Table 1.
SVT risk factors and prevalence of genetic thrombophilia.
| Trial | Patients | Risk Factor | Prevalence | ODDS Ratio |
|---|---|---|---|---|
| Karathanos et al. [23] | 128 SVT+ varicose veins vs. 102 varicose veins |
Protein S deficiency | OR 5.07 (95% CI 1.32–19.42), p = 0.018 | |
| Obesity | OR 5.50 (95% CI 2.16–13.99), p = 0.001 | |||
| Male patients | OR 2.02 (95% CI 1.01–4.02), p = 0.047 | |||
| Age > 70 years | OR 4.11 (95% CI 2.06–8.18), p = 0.001 | |||
| Age > 45 years | OR 2.28 (95% CI 1.29–4.01) | |||
| De Moerlose et al. [24] | 112 SVT vs. 180 healthy controls |
Factor V Leiden | 14.3% | OR 2.51 (95% CI 1.04–6.24) |
| Factor II G20210A | 3.6% | OR 3.28 (95% CI 0.46–36.84) | ||
| Margaglione et al. [25] | 105 SVT | Factor V Leiden | 16.2% | |
| Factor II G20210A | 7.6% | |||
| Martinelli et al. [26] | 63 SVT vs. 537 healthy controls |
Factor V Leiden | 15.9% | OR 6.1 (95% CI 2.6–14.2) |
| Factor II G20210A | 9.6% | OR 4.3 (95% CI 1.5–12.6) | ||
| AT III, protein C, and protein S deficiency | 10.2% | OR 6.64 (95% CI 2.6–46.2) | ||
| Lucchi et al. [27] | 73 SVT non-varicose veins |
Factor V Leiden | 51% | |
| MTHFR mutation | 38.3% | |||
| Factor II G20210A | 3.3% | |||
| Protein C deficiency | 1.6% | |||
| Protein S deficiency | 1.6% | |||
| Antiphospholipid antibodies | 8.3% | |||
| Legnani et al. [28] | 1294 SVT vs. 1294 healthy controls |
Protein C and protein S deficiency | OR 12.2 (95% CI 2.87–52.1), p < 0.001 | |
| Factor V Leiden | OR 2.97 (95% CI 2.15–4.10), p < 0.001 | |||
| Factor II G20210A | OR 1.37 (95% CI 0.95–1.98), p = 0.090 | |||
| Antiphospholipid antibodies | OR 2.92 (95% CI 0.91–9.40), p = 0.073 | |||
| Combined alterations | OR 26.1 (95% CI 3.48–196.3), p = 0.002 | |||
| High factor VIII Levels | OR 0.96 (95% CI 0.65–1.43), p = 0.862 |
Legend: OR: Odds Ratio and CI: Confidence Interval.